API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ELX-02 (exaluren) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside. It is being evaluated for the treatment of nonsense mutation alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
The proceeds will advance ELX-02 (exaluren sulfate), being developed for the treatment of Alport syndrome with nonsense mutations and other rare proteinuric kidney diseases, progress the development of ZKN-013 and to fund discovery efforts for the company’s TURBO-ZM™ platform.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Lead Product(s): Exaluren Sulfate
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
ELX-02 exaluren) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Lead Product(s): Exaluren Sulfate,Ivacaftor
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023